Cinryze offers
the power of
proven prevention

CINRYZE® (C1 esterase inhibitor [human]) is the first FDA-approved C1 esterase inhibitor (C1-INH) to help prevent HAE attacks in patients 6 years of age and older. CINRYZE has been proven to reduce attack frequency, severity, and the number of days of swelling.

Give your patients the power of prevention along their HAE journey.

Learn about CINRYZE

Scott, a real HAE
patient,
helps
prevent his

attacks with
CINRYZE

The first C1-INH therapy indicated to help prevent HAE attacks in adults, adolescents and pediatric patients (6 years of age and older)

CINRYZE® (C1 esterase inhibitor [human]) is the first FDA-approved C1 esterase inhibitor (C1-INH) to help prevent HAE attacks in patients 6 years of age and older. CINRYZE has been proven to reduce attack frequency, severity, and the number of days of swelling.

Give your patients the power of prevention along their HAE journey.

Put your patients on the path to prevention

Starting your patients on CINRYZE gives them access to preventive therapy along with resources and support for their journey with HAE.1

Learn about pediatric use

Find out more about the expanded indication of CINRYZE to include patients aged 6 to 11.

Learn more

Explore resources for patients

Patients can receive product support services from OnePath® Patient Support Managers and other OnePath team members as needed.

See product support services


See CINRYZE's efficacy

Safety and efficacy were evaluated in adults, adolescents, and children as young as 7.1

View study results

Request a sales representative

If you'd like to learn more about CINRYZE for your HAE patients, please get in touch.

Complete a request form

References

  1. CINRYZE® (C1 esterase inhibitor [human]) Prescribing Information. Shire.

Definition: